Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, 55280, Turkey.
University of California, San Francisco, School of Medicine, San Francisco, CA 94143, USA.
Immunotherapy. 2023 Aug;15(12):945-962. doi: 10.2217/imt-2022-0287. Epub 2023 Jun 9.
The impact of checkpoint inhibitors on gastroesophageal cancer treatment has been tremendous in the last 2 years. KEYNOTE-590, CHECKMATE 649 and CheckMate 648 are landmark trials that have introduced immunotherapy to the field as first-line therapy, leading to a paradigm change for advanced esophageal and gastric cancer. Chemotherapy in combination with immunotherapy is now the standard of care for first-line treatment of locally advanced or metastatic adenocarcinoma of the esophagus, esophagogastric junction and stomach. Several new targets and treatments are available for gastroesophageal cancer that are based on the characterization of cancer cells and the tumor microenvironment. Biomarker-based therapy selection is critical to optimize outcomes and minimize toxicities, as well as give insight into the optimal timing and sequence of a patient's treatment course.
在过去的 2 年中，检查点抑制剂对胃食管交界癌治疗的影响是巨大的。KEYNOTE-590、CHECKMATE 649 和 CheckMate 648 是具有里程碑意义的试验，它们将免疫疗法引入该领域作为一线治疗，为晚期食管和胃癌的治疗带来了范式转变。化疗联合免疫治疗现已成为局部晚期或转移性食管腺癌、食管胃交界癌和胃癌的一线治疗标准。基于癌细胞和肿瘤微环境的特征，目前有几种新的治疗靶点和治疗方法可用于胃食管交界癌。基于生物标志物的治疗选择对于优化疗效、最小化毒性以及深入了解患者治疗过程的最佳时机和顺序至关重要。
